Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Atyeo, 2020, Distinct early serological signatures track with SARS-CoV-2 survival, Immunity, 53, 524, 10.1016/j.immuni.2020.07.020 Gaebler, 2021, Evolution of antibody immunity to SARS-CoV-2, Nature, 591, 639, 10.1038/s41586-021-03207-w Isho, 2020, Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients, Sci Immunol, 5, 10.1126/sciimmunol.abe5511 Iyer, 2020, Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, Sci Immunol, 5, 10.1126/sciimmunol.abe0367 Ibarrondo, 2020, Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild COVID-19, N Engl J Med, 383, 1085, 10.1056/NEJMc2025179 Anand, 2021, Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset, Cell Rep Med, 2 Wajnberg, 2020, Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Science, 370, 1227, 10.1126/science.abd7728 Dan, 2021, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Science, 371, 10.1126/science.abf4063 Hall, 2021, SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicenter, prospective cohort study (SIREN), The Lancet, 397, 1459, 10.1016/S0140-6736(21)00675-9 Hansen, 2021, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study, Lancet, 397, 1204, 10.1016/S0140-6736(21)00575-4 Lumley, 2021, Antibody status and incidence of SARS-CoV-2 infection in health care workers, N Engl J Med, 384, 533, 10.1056/NEJMoa2034545 Andreano, 2021, SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies, Nat Med, 27, 759, 10.1038/s41591-021-01347-0 Davies, 2021, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, 372 Hu, 2021, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies, Cell Mol Immunol, 18, 1061, 10.1038/s41423-021-00648-1 Sabino, 2021, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence, Lancet, 397, 452, 10.1016/S0140-6736(21)00183-5 Tegally, 2021, Detection of a SARS-CoV-2 variant of concern in South Africa, Nature, 592, 438, 10.1038/s41586-021-03402-9 Prendecki, 2021, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine, Lancet, 397, 1178, 10.1016/S0140-6736(21)00502-X Velay, 2020, Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies, Diagn Microbiol Infect Dis, 98, 10.1016/j.diagmicrobio.2020.115181 Fafi-Kremer, 2020, Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France, EBioMedicine, 59, 10.1016/j.ebiom.2020.102915 Planas, 2021, Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies, Nat Med, 27, 917, 10.1038/s41591-021-01318-5 McKay, 2020, Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice, Nat Commun, 11, 3523, 10.1038/s41467-020-17409-9 Mickey, 1989, The impact of confounder selection criteria on effect estimation, Am J Epidemiol, 129, 125, 10.1093/oxfordjournals.aje.a115101 Capetti, 2021, One-year durability of anti-spike IgG to SARS-CoV-2: preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG, J Infect, 83, 237, 10.1016/j.jinf.2021.05.023 Choe, 2021, Persistence of neutralizing antibody response up to one year after asymptomatic or symptomatic SARS-CoV-2 infection, J Infect Dis, 339 Masiá, 2021, Durable antibody response one year after hospitalization for COVID-19: a longitudinal cohort study, J Autoimmun, 123, 10.1016/j.jaut.2021.102703 Li, 2021, Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan, Nat Commun, 12, 4144, 10.1038/s41467-021-24230-5 Dobaño, 2021, Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19, BMC Med, 19, 155, 10.1186/s12916-021-02032-2 Wang, 2021, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection, Nature, 595, 426, 10.1038/s41586-021-03696-9 Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity, Nat Commun, 11, 4704, 10.1038/s41467-020-18450-4 Muecksch, 2021, Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients, J Infect Dis, 223, 389, 10.1093/infdis/jiaa659 Takahashi, 2020, Sex differences in immune responses that underlie COVID-19 disease outcomes, Nature, 588, 315, 10.1038/s41586-020-2700-3 Fischinger, 2019, Sex differences in vaccine-induced humoral immunity, Semin Immunopathol, 41, 239, 10.1007/s00281-018-0726-5 Scully, 2020, Considering how biological sex impacts immune responses and COVID-19 outcomes, Nat Rev Immunol, 20, 442, 10.1038/s41577-020-0348-8